Goldman Sachs on Tuesday reclassified M&G Plc (LON:MNG) to a "neutral" recommendation and lowered its 12-month price target to 320p from 330p. The adjustment follows a period in which the insurer’s shares have risen by in excess of 50% over the past year, materially outperforming UK life peers and the STOXX600 by roughly 30-35 percentage points and prompting a pullback in the stock.
The broker highlighted that the stock was trading at 297.2p as of April 20, a level that implies about 7.7% upside to the newly set target. Goldman Sachs noted several valuation and yield signals that underpin the downgrade. The 1-year forward consensus price-to-earnings multiple has shifted toward the top end of its historical range, and the company’s dividend yield has fallen close to its lowest post-listing levels, moving the yield to nearer the sector midpoint.
On a comparative basis within the brokerage’s coverage universe for life insurers, M&G’s estimated total capital return yield for 2027 ranks second-lowest. Those valuation considerations weigh alongside questions about how surplus capital might be deployed, the firm said.
Goldman Sachs attributed the recent advance in M&G’s share price to three principal developments. First, a strategic partnership announced on May 30, 2025 with Japan’s largest insurer, Dai-ichi Life, which Goldman Sachs expects to generate at least $6 billion of flows over five years. Under that arrangement, Dai-ichi intends to build a stake of approximately 15% in M&G through on-market purchases, subject to regulatory clearance. Second, the broker pointed to improving asset management and PruFund net flows across 2025. Third, there has been an approximate 11% upgrade to 2027 consensus operating profit estimates since the start of 2025.
In response to market moves during the first quarter of 2026, Goldman Sachs adjusted its financial model and trimmed its EPS forecasts for 2026-2030 by about 3% on average. The reduction was attributed to a combination of higher interest rates and diminished equity markets, which have put pressure on asset management assets under management. The bank’s freshly published EPS projection for 2026 is 29.41p, down from 30.23p, while its 2027 EPS estimate is 32.61p versus a prior 33.69p.
Goldman Sachs also said its own operating profit and operating capital generation projections are broadly aligned with Visible Alpha Consensus Data. Even with an improvement in M&G’s Solvency II ratio - from 203% in 2023 to 242% in 2025 - the broker does not expect additional capital returns in the near term, citing an active debate over how deployable the insurer’s excess capital actually is.
Despite the downgrade, Goldman Sachs indicated that M&G’s 2027 ambitions remain reachable. The company’s public targets include adjusted operating profit annual growth of 5% or more, roughly 2.7 billion of operating capital generation over 2025-27, and an asset management cost-to-income ratio of about 70%. The broker’s modelling implies a 7.3% compound annual growth rate for operating profit and 2.8 billion in total operating capital generation for that period.
The revised 12-month price target of 320p is derived using an unchanged multiple of approximately 1.1x price-to-adjusted tangible book value. Goldman Sachs observed that this multiple sits above an implied 0.8x level from a sector regression, a premium the bank attributes to M&G’s "relatively capital-light business model."
Overall, the downgrade reflects Goldman Sachs’ view that much of the stock’s near-term upside has been consumed by the strong rally and that several valuation and capital-deployment questions remain to be resolved despite the company meeting many of its operational targets.
Summary
Goldman Sachs moved M&G to neutral and cut its 12-month target to 320p after a >50% share price rally pushed valuation metrics toward the upper end of historical ranges, compressed dividend yield, and left limited upside relative to the new target. The broker also trimmed near-term EPS forecasts in light of Q1 2026 market dynamics and signalled uncertainty around the deployability of M&G’s excess capital despite an improved Solvency II ratio.
Key points
- Goldman Sachs downgraded M&G to neutral and lowered the price target to 320p from 330p; the stock was 297.2p on April 20, implying 7.7% upside.
- Valuation stretched - forward P/E moved toward the top of its historical band and dividend yield is near post-listing lows; 2027 total capital return yield ranks second-lowest among covered life insurers.
- Drivers of the 12-month rally include the May 30, 2025 Dai-ichi Life partnership expected to bring at least $6 billion of flows over five years, improved asset management and PruFund flows in 2025, and an ~11% upgrade to 2027 operating profit consensus since early 2025.
Risks / uncertainties
- Valuation risk - elevated forward P/E and compressed dividend yield could limit further share-price upside in the near term - impacting UK life insurers and broader UK equities.
- Capital-deployment uncertainty - despite a stronger Solvency II ratio, debate persists on how deployable excess capital is, affecting expectations for shareholder distributions and sector capital management.
- Market-sensitivity risk - Goldman Sachs reduced EPS forecasts after Q1 2026 market moves, noting higher interest rates and weaker equity markets can depress asset management AUM and earnings - relevant to asset managers and insurers with large AUM exposures.